Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vedolizumab subcutaneous long-term open-label extension in pediatric ulcerative colitis or Crohn's disease
2023-508804-39-00Phase 3Authorised
- Sponsor
- Takeda
- Start
- Oct 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 16
01
Overview
Phase 3, open-label trial of vedolizumab in autoimmune colitis and Crohn's disease (2 cohorts), sponsored by Takeda. Primary endpoints: Incidence of safety events and Incidence of AEs, SAEs, and AESIs. Planned start Oct 2025; status: authorised.
02
Drugs
vedolizumab
03
Conditions
autoimmune colitisCrohn's disease
Beyond the preview
Go deeper on 2023-508804-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508804-39-00.